ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
ZYUS Strengthens Leadership Team with Appointment of VP of Clinical Research
TORONTO--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) is pleased to announce that it has entered into a debt exchange agreement to settle a certain outstanding promissory note in the aggregate amount of $1,000,000 CAD (the “Debt”) owing to a certain arm’s length creditor (the “Creditor”) with a due date of June 30, 2024 through the issuance of 1,000,000 common shares of the Company (the “Common Shares”) at a deemed price of $1.00 per Common Share (the “Transaction”).
ZYUS Life Sciences Corporation Reports Q3 2023 Results
ZYUS Life Announces Positive Phase I Trial Results for Trichomylin® Softgels
ZYUS Life Announces New Director of Investor Relations and Capital Markets
PHILADELPHIA--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com.